PHARMARON BIOLOGICS (UK) LTD

• ⚠

  Material uncertainty over going concern

  The directors believe that preparing the financial statements on the going concern basis is appropriate. Forecasts prepared on the basis of the current costs model show that the Company will need financial support from its ultimate parent, Pharmaron. The directors have received a letter of support from Pharmaron for a period of 12 months from the date of approval of these financial statements in order to ensure that the Company can meet its obligations as they fall due.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -4.9%

  £29,346,682 → £27,910,856

• Cash

  +6.6%

  £11,097,343 → £11,831,577

• Net assets

  +26.5%

  £59,879,869 → £75,742,104

• Employees

  +2.2%

  183 → 187

• Operating profit

  +38.7%

  -£1,132,135 → -£693,959

• Profit before tax

  +68.9%

  -£1,001,087 → -£311,147

• Wages

  -2.1%

  £11,481,476 → £11,235,855

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. PHARMARON BIOLOGICS (UK) LTD 2021-05-14 → present
2. ALLERGAN BIOLOGICS LIMITED 2016-01-07 → 2021-05-14
3. ACTAVIS BIOLOGICS LIMITED 2014-03-31 → 2016-01-07
4. EDEN BIODESIGN LIMITED 2002-11-20 → 2014-03-31
5. HALLCO 826 LIMITED 2002-09-24 → 2002-11-20

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Azets Audit Services

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The directors believe that preparing the financial statements on the going concern basis is appropriate. Forecasts prepared on the basis of the current costs model show that the Company will need financial support from its ultimate parent, Pharmaron. The directors have received a letter of support from Pharmaron for a period of 12 months from the date of approval of these financial statements in order to ensure that the Company can meet its obligations as they fall due.”

Significant events

• “The Company continued to make significant investment in capital assets during 2024 to replace end of life systems and develop innovative technologies to remain competitive in the marketplace and comply with UK and global regulatory standards.”
• “The Company continued its ambitious £89.3m, 8,000m2 expansion project on site in Liverpool.”
• “The building shell was completed May 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.